| Date |
Subject |
Media |
| 2025-08-06 |
China Medical University Launches AI Medical Robotics Initiative
|
AI-powered robots are booming, and major medical institutions are pushing for widespread adoption. Chang-Hai Tsai, Chairman of China Medical University and Healthcare System, stated that the CMU system will focus on the development of intelligent medical robots, including care robots, companion robots, disinfection robots, and nursing robots. The university will continue to collaborate with leading technology companies and innovation teams to jointly develop a new generation of smart robots. |
| 2025-08-06 |
Acepodia Biotechnologies Eyes ADC Market Boom, Plans to Spin Off New Company and Attract U.S. and European Investment
|
Targeting the booming antibody-drug conjugate (ADC) market, Acepodia Biotechnologies Chairman Sonny Hsiao announced on the 14th that the company plans to spin off its bispecific antibody dual-drug conjugation platform into a new entity, contributing the technology as capital. The new company aims to attract American investors, with the goal of completing the setup by the end of this year and raising $50–60 million USD to accelerate development of the platform technology. |
| 2025-08-06 |
Sinphar Advances Global Expansion with Multiple International Partnership Agreements
|
On July 14, Sinphar Pharmaceutical announced a major step forward in its internationalization efforts. During the Interphex Japan exhibition held this July, Sinphar’s General Manager, Yu-Liang Pei, personally led a team to Japan, where the company successfully signed several cross-border cooperation agreements. The team also held in-depth discussions regarding pharmaceutical contract manufacturing and import sales, further strengthening its market presence in Taiwan and across Asia. |
| 2025-08-06 |
Flat Medical Accelerates Global Expansion with Continued Breakthroughs in Anesthesia and Pain Localization Technology
|
Taiwanese medical technology company Flat Medical has been steadily advancing both technologically and commercially in the global anesthesia and pain management sector in recent years. Since entering mass production and sales in 2023, its flagship product, the EpiFaith® smart locator, has experienced rapid growth with an annual increase of 3 to 4 times in sales volume. Cumulative shipments have surpassed tens of thousands of units, establishing a solid presence across key markets including Europe, the United States, Japan, South Korea, and Taiwan. |
| 2025-08-06 |
Brighten Optix Reports June Revenue of NT$48.68 Million, Up 4.8% Month-on-Month; First Half Revenue Grows 3.1% Driven by Two Key Factors
|
Brighten Optix announced on the 10th that its consolidated revenue for June reached NT$48.68 million, a 4.81% increase compared to the same period last year. The company’s consolidated revenue for the first half of the year totaled NT$368 million, up 3.1% year-on-year, primarily benefiting from strong growth in emerging markets across the Asia-Pacific region and continued strong sales of its three-in-one myopia control kit. |
| 2025-08-06 |
Darwin Precisions Corporation Expands into Diverse Fields
|
Michael Tsai, Chairman of Darwin Precisions Corporation, stated that the company is no longer just a display manufacturer but now provides comprehensive solutions that truly address customer needs. With new applications gradually coming to fruition, Darwin is actively expanding into multiple fields, embarking on a new phase of growth. |
| 2025-08-06 |
Dual Engines Drive Growth: GeneReach Biotechnology’s June Revenue Up 66% Year-on-Year
|
GeneReach Biotechnology announced consolidated revenue of NT$17.31 million for June 2025, a 3.26% month-on-month decrease but a 65.54% increase compared to the same period last year. The company’s cumulative revenue for the first half of the year reached NT$107 million, representing a 20.10% year-on-year growth. GeneReach stated that in the second half of the year, it will further strengthen its global market presence, deepen penetration in existing markets, and continue to explore emerging market potential in South America, focusing on Ecuador and Paraguay, aiming to inject steady operational momentum. |
| 2025-08-06 |
Breakthrough in Pulmonary Hypertension Diagnosis: Results in 10 Minutes
|
Pulmonary hypertension is a highly fatal cardiopulmonary disease that often suffers from delayed diagnosis due to subtle early symptoms, increasing patient mortality risk. Taipei Veterans General Hospital recently announced a major research breakthrough, completing the world’s first multinational and multicenter validation of an "ECG-Based Pulmonary Hypertension Detection System." This system can automatically analyze electrocardiograms within 10 minutes and instantly transmit positive high-risk patient results to clinicians, assisting in timely scheduling of further examinations such as echocardiography, thereby improving survival rates. |
| 2025-08-06 |
Bora Pharmaceuticals Reports H1 Revenue Surpassing NT$10 Billion, Up 26.9%, Setting Historical Record
|
Bora Pharmaceuticals announced on the 10th that its preliminary consolidated revenue for June reached NT$1.65 billion, a 2.7% decrease compared to the same period last year. When measured in U.S. dollars, however, June revenue grew 10.3% from May and increased 3.4% year-over-year. The main factor for this discrepancy was the appreciation of the New Taiwan dollar. For the first half of this year, Bora’s cumulative revenue exceeded NT$10 billion, representing a 26.9% year-on-year increase and setting a new historical record for the period. Overall operations continue to show steady growth. |
| 2025-08-06 |
Gongwin Biopharm’s U.S. Subsidiary to Receive $50 Million Investment from Fund A for Clinical Trials in the U.S.
|
Gongwin-KY announced on the evening of July 10 that its subsidiary, Gongwin Biopharm, received a letter of intent (LOI) from Fund A on July 9. Fund A plans to participate in the establishment of Gongwin’s U.S. subsidiary and intends to invest up to $50 million USD (approximately NT$1.462 billion), representing about half of the Series A fundraising target of $100 million USD. This round of fundraising is expected to release approximately 20% to 25% of the equity. |
